<DOC>
	<DOCNO>NCT01722864</DOCNO>
	<brief_summary>A study show safety COV155 patient osteoarthritis knee hip moderate severe chronic low back pain .</brief_summary>
	<brief_title>Open Label Safety Tolerability Study COV155 Subjects With Osteoarthritis ( OA ) Chronic Low Back Pain ( CLBP )</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Osteoarthritis , Hip</mesh_term>
	<criteria>Inclusion Criteria General good health , osteoarthritis ( OA ) chronic low back pain ( CLBP ) , base upon result medical surgical history medical exam ≥18 year age Voluntarily provide write informed consent Female subject eligible 1 . Not pregnant lactating ; plan become pregnant within next 60 day 2 . Surgically sterile , 2 year postmenopausal , practice acceptable birth control 60 day prior Screening use acceptable birth control study 7 day follow last dose COV155 Male subject biologically capable child must use reliable birth control study 7 day last dose COV155 . Surgical sterilization subject 's monogamous partner qualifies adequate birth control Clinical diagnosis one follow 1 . OA knee hip least 1 year moderate severe daily pain despite chronic use stable dos nonsteroidal antiinflammatory drug ( NSAIDs ) nonsteroidal , nonopioid therapy therapy include opioids 2 . Moderate severe CLBP least several hour day minimum 90 day , due know malignancy , classify nonneuropathic , neuropathic , symptomatic 6 month LBP surgery 3 . OA knee schedule undergo unilateral primary tricompartmental arthroplasty . For CLBP/OA : Average inclinic pain score ≥3 11point ( 0 10 ) numerical rating scale ( NRS ) average last 24 hour Screening ; Pain intensity score ≥4 NRS average last 24 hour Baseline For TKR : 11 . Postoperative pain intensity score ≥ 4 0 10 NRS discontinuation postsurgical patient control analgesia intravenous pain medication ; body mass index ≤ 38.0 ; classify either Physical Status ( PS ) 1 PS2 . Exclusion Criteria Any clinically significant condition unstable illness precludes study participation interferes assessment pain symptom CLBP OA would increase risk opioid NSAID related adverse event Schizophrenia uncontrolled poorly control major psychiatric condition clinically significant anxiety depression Active malignancy history malignancy within 2 year prior Screening dermal cervical squamous cell carcinoma situ History seizure ( exceptionpediatric febrile seizure ) Clinically significant ECG abnormality uncontrolled hypo hypertension For CLBP/OA : Arthroscopic open surgery either knee hip select primary OA study joint within 6 month prior Screening ; For CLBP subject , surgical procedure back pain within 6 month prior Screening , nerve plexus block within 30 day prior Screening botulinum toxin injection lower back region within 90 day prior Screening . For OA subject , joint injection within 30 day prior Screening ; Surgical implant either knee hip select primary OA joint ; history spinal stenosis ( CLBP subject ) For TKR : Major prior open knee surgery side arthroplasty ; surgery/elective procedure within 4 week Screening , study ; go rehabilitation surgery Gastric reduction gastric band surgery Taking opioids equivalent 20 mg hydrocodone 40 mg morphine orally per day , take opioid medication 4 day week Known allergy hypersensitivity opioids , acetaminophen ibuprofen Certain lab abnormality Unable discontinue use prohibit medication history substance alcohol abuse within 2 year prior Screening positive urine drug test Screening alcohol , illicit drug ( include medical cannabis ) control substance prescribe medication Positive human immunodeficiency virus , hepatitis B ( surface antigen ) , and/or hepatitis C Any chronic pain condition CLBP OA would interfere assessment CLBP OA Used monoamine oxidase inhibitor , antipsychotic , benzodiazepine within 14 day prior Screening start change dos anticonvulsant , selective serotonin reuptake inhibitor , serotonin norepinephrine reuptake inhibitor , tricyclic antidepressant within 30 day prior Screening Previously receive COV155 study Received investigational drug device within 30 day prior Screening Other criterion specify protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>